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PRECLINICAL STUDY
ttenuation by Metallothionein of
arly Cardiac Cell Death via Suppression
f Mitochondrial Oxidative Stress Results
n a Prevention of Diabetic Cardiomyopathy
u Cai, MD, PHD,*†‡ Yuehui Wang, MD, PHD,* Guihua Zhou, MD, PHD,* Teresa Chen, PHD,†
e Song, MD, PHD,* Xiaokun Li, MD, PHD,‡ Y. James Kang, DVM, PHD*†
ouisville, Kentucky; and Wenzhou, China
OBJECTIVES We aimed to test whether attenuation of early-phase cardiac cell death can prevent diabetic
cardiomyopathy.
BACKGROUND Our previous study showed that cardiac apoptosis as a major early cellular response to diabetes is
induced by hyperglycemia-derived oxidative stress that activates a mitochondrial cytochrome
c-mediated caspase-3 activation pathway. Metallothionein (MT) as a potent antioxidant prevents
the development of diabetic cardiomyopathy.
METHODS Diabetes was induced by a single dose of streptozotocin (STZ) (150 mg/kg) in cardiac-
specific, metallothionein-overexpressing transgenic (MT-TG) mice and wild-type (WT)
controls. On days 7, 14, and 21 after STZ treatment, cardiac apoptosis was examined by
terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and
caspase-3 activation. Cardiomyopathy was evaluated by cardiac ultrastructure and fibrosis in
the diabetic mice 6 months after STZ treatment.
RESULTS A significant reduction in diabetes-induced increases in TUNEL-positive cells, caspase-3
activation, and cytochrome c release from mitochondria was observed in the MT-TG mice as
compared to WT mice. Cardiac protein nitration (3-nitrotyrosine [3-NT]) and lipid
peroxidation were significantly increased, and there was an increase in mitochondrial oxidized
glutathione and a decrease in mitochondrial reduced glutathione in the WT, but not in the
MT-TG, diabetic mice. Double staining for cardiomyocytes with alpha sarcomeric actin and
caspase-3 or 3-NT confirmed the cardiomyocyte-specific effects. A significant prevention of
diabetic cardiomyopathy and enhanced animal survival were observed in the MT-TG diabetic
mice as compared to WT diabetic mice.
CONCLUSIONS These results suggest that attenuation of early-phase cardiac cell death by MT results in a
significant prevention of the development of diabetic cardiomyopathy. This process is
mediated by MT suppression of mitochondrial oxidative stress. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.02248:1688–97) © 2006 by the American College of Cardiology Foundation
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fardiac dysfunction has become the major cause of mortal-
ty in diabetic patients (1–3). Diabetic cardiomyopathy was
ound not directly related to vascular pathogenesis (2,3), but
he precise mechanism remains elusive (1–3). Hearts from
iabetic patients and streptozotocin (STZ)-induced diabetic
nimals display a reduction in cardiac mass over time and
nterstitial and perivascular fibrosis at late phase (2–5).
hese late-phase changes, however, are believed to result
rom early cellular responses such as cardiac cell death
2,4,6,7).
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ccepted June 19, 2006.Cardiac apoptosis as a comprehensive consequence of
ardiac responses to various stresses causes a loss of contrac-
ile tissue, which initiates a cardiac remodeling and fibrosis;
herefore, the cardiac apoptosis has been identified as a
ivotal cause of various cardiomyopathies (8–10). We, as
ell as others, have shown that cardiac apoptosis increases
n diabetic animals and patients (11–14). It remains to be
etermined whether the increased cardiac apoptotic cell
eath plays an important role in the development of diabetic
ardiomyopathy (7).
Mitochondrial cytochrome c release and activation of
aspase-3 play an important role in diabetes-induced cardiac
ell death (14,15). Among apoptotic stimuli, reactive oxy-
en species (ROS) or reactive nitrogen species (RNS) play a
ritical role in the mitochondrial cytochrome c release and
aspase-3 activation (7,8,14–17). A significant increase in
OS and RNS was found in cardiac cells exposed to high
evels of glucose in vitro (14) and in isolated cardiomyocytes
rom diabetic mice (13,18). We have further identified an
ncreased accumulation of superoxide with an increase in
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October 17, 2006:1688–97 MT Prevents Diabetic Cell Death and Cardiomyopathyrotein nitration (measured by 3-nitrotyrosine [3-NT]) in
he hearts of diabetic mice (19). Therefore, we hypothesize
hat diabetes-derived oxidative and/or nitrosative damage
auses an early-stage cell death that activates a series of
ardiac remodeling responses, leading to morphological and
unctional abnormalities, and eventually to cardiomyopathy
t the late stage (7).
Metallothioneins (MTs), a group of intracellular metal-
inding proteins with high cysteine contents, are able to
fficiently protect cells or tissues from oxidative damage
20–22). By functional examination, the preventive effect of
T against diabetes-induced cardiac injury has been dem-
nstrated in our recent studies (19,23) and also in other
tudies (18,24). In the present study, we used cardiac-
pecific, MT-overexpressing transgenic (MT-TG) mice to
etermine (1) whether MT can prevent diabetes-induced
ardiac apoptosis at early stage via suppression of oxidative
tress, and (2) whether MT’s attenuation of diabetes-
nduced early-stage cardiac apoptosis can result in a preven-
ion of the development of cardiomyopathy at late stage.
ATERIALS AND METHODS
iabetic mouse model. Cardiac-specific, MT-TG mice
ere produced from FVB mice, originally obtained from
arlan Bioproducts for Science (Indianapolis, Indiana) and
haracterized as described in a previous study (22). Metal-
othionein is overexpressed only in cardiac myocytes without
lterations of other antioxidants, including glutathione
GSH), glutathione peroxidase (Gpx), glutathione reduc-
ase (GR), catalase, and superoxide dismutase (22). Both
T-TG and wild-type (WT) mice were housed in the
niversity of Louisville Research Resources Center at 22°C
ith a 12-h light/dark cycle and were provided free access to
tandard rodent chow and tap water. All animal procedures
ere approved by the Institutional Animal Case and Use
Abbreviations and Acronyms
ANOVA analysis of variance
Gpx  glutathione peroxidase
GR  glutathione reductase
GSH  glutathione
GSSG  oxidized glutathione
IGF-1  insulin-like growth factor 1
LVEDP  left ventricular end-diastolic pressure
MT  metallothionein
MT-TG  cardiac-specific, metallothionein-
overexpressing transgenic
RNS  reactive nitrogen species
ROS  reactive oxygen species
STZ  streptozotocin
TBARS  thiobarbituric acid-reactive substance
3-NT  3-nitrotyrosine
TUNEL  terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling
WT  wild-typeommittee, which is certified by the American Association bor Accreditation of Laboratory Animal Care. Eight-week-
ld, male mice were intraperitoneally administrated a single
ose of STZ (Sigma Co., St. Louis, Missouri) at 150 mg/kg
ody weight, dissolved in sodium citrate buffer (pH 4.5). On
ay 3 after STZ treatment, whole-blood glucose obtained
rom the mouse tail-vein was monitored using the SureStep
omplete blood glucose monitor (LifeScan Inc., Milpitas,
alifornia). Streptozotocin-treated mice with whole-blood
lucose higher than 12 mmol/l were considered diabetic. To
liminate possible confounding effects of STZ on the early
ell death, insulin-treated diabetic mice were examined 14
ays after STZ treatment. When hyperglycemia was diag-
osed on day 3 after STZ treatment, insulin was immedi-
tely given using a long-term insulin preparation (Humulin
, Eli Lilly and Company, Indianapolis, Indiana) at a
oncentration of 10 U/mouse twice a day to maintain the
lood glucose levels between 5.6 and 11.2 mmol/l, with an
verage of 7.6  1.1 mmol/l.
erminal deoxynucleotidyl transferase-mediated dUTP
ick end labeling (TUNEL) assay. Cardiac sections in
araffin were prepared as before (14) and were processed for a
UNEL assay using an ApopTag in situ detection kit from
ntergen (Purchase, New York). Mouse testicular tissue was
sed as positive control. For negative control, terminal de-
xynucleotidyltransferase was omitted from the reaction mix-
ure. The apoptotic cell death was quantitatively analyzed by
ounting the TUNEL-positive cells randomly selected from 5
elds from each of the 3 slides from each mouse.
etection of cardiac caspase-3. Caspase-3 activation was
easured by Western blotting, based on a published
ethod (15). Briefly, cardiac tissue homogenates were lysed
nd fractionated electrophoretically on sodium dodecyl (lau-
yl) sulfate polyacrylamide gel electrophoresis (15% gradient
els), and proteins were transferred to a nitrocellulose
embrane. The membrane was blocked with a 5% non-fat,
ried milk for 1 h and subsequently incubated with the
rimary antibody against the active form of caspase-3
Sigma, St. Louis, Missouri) at 1:500 overnight at 4°C.
fter the unbound antibodies with Tris-buffered saline (pH
.2) containing 0.05% Tween 20 (Bio-Rad Laboratories,
ercules, California) were removed, the membrane was incu-
ated with the secondary antibody for 2 h at room temperature.
lyceraldehyde-3-phosphate dehydrogenase protein expres-
ion was probed as an internal control.
Caspase-3 activation was also examined by caspase-3 activity
s described before (14). Briefly, fresh heart tissues were
omogenized with Telfon homogenizer in an extract buffer,
nd the homogenate was centrifuged at 20,000 g for 30 min.
he supernatant was diluted with an assay buffer and incubated
t 37°C with 200 mol/l caspase-3 substrate I (Ac-DEVD-
NA [N-acetyl-asp-glu-val-asp-pNA], CalBiochem, La Jolla,
alifornia). Cleavage of the substrate was monitored at 405
m using a microplate reader and recorded in 10-mm intervals
or 2 h.
The localization of the activated caspase-3 was determined
y double stains for cardiomyocyte and caspase-3, on the basis
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MT Prevents Diabetic Cell Death and Cardiomyopathy October 17, 2006:1688–97f a published study (25). Briefly, cardiac tissues were fixed
ith 75% alcohol and embedded in paraffin. Tissue sections at
-m thickness were deparaffinized and rehydrated in a graded
lcohol series. Sections were incubated with cocktail primary
ntibodies overnight at 4°C. The cocktail primary antibodies
ncluded a mouse anti--sarcomeric actin monoclonal anti-
ody (Abcom Inc., Cambridge, Massachusetts) and rabbit
nti-active caspase-3 polyclonal antibody (Becton Dickinson,
ranklin Lakes, New Jersey), both at a final dilution of 1:50.
fter being washed with phosphate-buffered saline, sections
ere incubated with cocktail secondary antibodies, fluorescein
sothiocyanate-conjugated rabbit anti-mouse IgG  IgM 
gA (Abcam Inc., Cambridge, Massachusetts) at a dilution of
:40 and Cy3-conjugated goat anti-rabbit IgG H & L (Abcom
nc.) at a dilution of 1:100, for 1 h in darkness at room
emperature. Sections were examined using confocal laser
canning microscopy (Zeiss LSM510, Carl Zeiss Meditec Inc.,
ublin, California) at emission of 500 to 530 nm and 550 to
60 nm, after excitation at 488 and 543 nm, respectively. Laser
ower and detection gains were set such that signals from
ingle-stained controls would not appear in adjacent channels.
egative controls were realized on specimens incubated either
ith nonimmune serum or with the incubation buffer alone,
ollowed by the second conjugated antibody.
etection of mitochondrial cytochrome c release. Cyto-
olic and mitochondrial proteins were prepared for Western
lotting assay to detect cytochrome c content, as previously
escribed (14). Densitometry analysis for each band was
erformed using the computer program as described above,
nd quantitative data are presented as relative to control.
easurements of mitochondrial GSH, GSSG, Gpx, and
R. To obtain sub-cellular fractionations (cytosolic and
itochondrial), heart tissue (3 mouse hearts were pooled as
sample) was homogenized with cold HMS (220 mmol/l
-Mannitol, 70 mmol/l sucrose, 2 mmol/l K-HEPES, pH
.4) and centrifuged at 4°C for 5 min at 600  g. The
upernatants were further centrifuged at 7,000  g for 10
in. The heavy membrane fraction (mitochondria) was
ashed once again in HMS by centrifugation at 600 g for
min to remove any contaminating particles and then
ecovered by centrifugation at 7,000  g for 10 min. The
solated mitochondria were resuspended in incubation buffer
250 mmol/l sucrose, 10 mmol/l K-HEPES, pH 7.2,
mmol/l KH2PO4, 5 mmol/l sodium succinate, 2.5 mmol/l
GTA). The cytosol and mitochondria were then frozen
mmediately for GSH and oxidized glutathione (GSSG)
ssay. Glutathione and GSSG contents were simultaneously
uantified by high-performance liquid chromatography
ith dual electrochemical detection (26).
The mitochondrial proteins were also used to measure
px and GR using the Glutathione Peroxidase Cellular
ctivity Assay Kit and the Glutathione Reductase Assay Kit
Sigma, St. Louis, Missouri). Both GR and Gpx activities
ere calculated using the extinction coefficient of 6.22
mol/l1 cm1, and expressed as nmol/l of nicotinamide ddenine dinucleodtide phosphate consumed per minute per
illigram of sample protein (22).
ssay for lipid peroxidation. Cardiac lipid peroxidation was
uantified by measuring thiobarbituric acid-reactive substance
TBARS) as described previously (21). The TBARS concen-
rations were expressed as nmol/g tissue.
ouble staining for cardiomyocytes and protein nitra-
ion. To determine whether protein nitration occurs in the
ardiomyocytes, double stains for cardiomyocytes by
-sarcomeric actin and protein nitration by 3-NT were
erformed using confocal laser scanning microscopy (25), as
reviously described except for the primary antibody (i.e.,
sing a rabbit anti-3-NT polyclonal antibody at 1:50 dilu-
ion [Chemicon Inc., Temecula, California]).
ltrastructural examination by electron microscopy. The
earts subjected to electron microscopic examination were
xed in situ by vascular perfusion with saline for 10 min,
ollowed by a Karnovsky’s fixative (2% paraformaldehyde and
.5% glutaraldehyde in cacodylate buffer, pH 7.4) for 15 min.
he in situ fixative perfusion procedure and semi-quantitative
nalysis were described in our previous studies (19,22).
irius-red staining of collagen. Tissue sections of 5 m
ere used for Sirius-red staining of collagen using 0.1%
irius-red F3BA and 0.25% fast green FCF. The sections
tained for Sirius red then were assessed for the proportion
f fibrosis (collagen) using a computer-assisted image-
nalysis system as described in our previous study (23).
tatistical analysis. Data were collected from repeated
xperiments and are presented as mean SD. Comparisons
etween 2 groups with normality and homogeneity of
ariances were performed by 2-tailed unpaired Student
test. Alternatively, comparisons between groups with
bnormality and heterogeneity of variances were performed
y Welch t test. One-way analysis of variance (ANOVA)
as used, followed by the post-hoc Tukey multiple com-
arison test to analyze data for WT mice when the
nsulin-treated diabetic group was included (Figs. 1 and
A). Disclaimer concerning type 1 error rate is a limitation
f this study, since no correction for multiple comparisons
as applied. The SPS 9.1 system (SAS Institute Inc., Cary,
orth Carolina) was used for all statistical tests. Differences
ere considered to be significant at p  0.05.
ESULTS
nhibition of apoptosis in the hearts of MT-TG diabetic
ice. Both WT and MT-TG diabetic mice showed in-
reased whole-blood glucose levels (Fig. 1A) and glycated
emoglobin (Fig. 1B) on the 14th and 21st day after STZ
reatment. These changes were prevented by supplementation
ith insulin in the WT diabetic mice (Figs. 1A and 1B).
ecause we have shown that diabetes caused a significant
ncrease in cardiac apoptotic cell death from day 7 to day 21
fter STZ treatment (14), TUNEL assay was performed in the
ardiac tissues from both WT and MT-TG mice 7, 14, and 21
ays after STZ treatment. An increased apoptosis (i.e.,
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October 17, 2006:1688–97 MT Prevents Diabetic Cell Death and CardiomyopathyUNEL-positive cells; Fig. 1C) was observed in the hearts of
T diabetic mice, but not in MT-TG diabetic mice. No
ignificant difference was found among the results examined on
ays 7, 14, and 21 after STZ treatment; therefore, a combined
esult of TUNEL-positive cells from these 3 time points as
he early-phase apoptotic cell death was quantitatively
ummarized in Figure 1D. Results show that a significant
ncrease in cardiac apoptosis was observed in the WT
iabetic mice, but not in the insulin-treated WT diabetic
r MT-TG diabetic mice.
To confirm the inhibitory effect of MT on diabetes-
nduced cardiac apoptosis, caspase-3 activation, another
mportant indication of apoptosis, was measured by its
ctivity and the content of its active form using enzymatic
igure 1. Diabetic model and diabetes-induced cardiac apoptosis. Whole-
iabetic mice 14 days after streptozotocin (STZ) treatment. Cardiac apopto
nd labeling (TUNEL) assay. Panel C presents the representatives of TU
reatment and panel D presents combined results for the quantitative analy
to day 21 after STZ treatment. Data were presented as mean values 
ANOVA) was used followed by the post-hoc Tukey multiple comparis
etallothionein-overexpressing transgenic mice, WT  wild-type mice.nd Western blotting assays (Fig. 2). Enzymatic assay ohowed a significant increase in caspase-3 cleavage activity
n the WT diabetic heart, but not in the insulin-treated WT
iabetic or MT-TG diabetic heart (Fig. 2A). Consistent
ith the activity assay, Western blotting analysis also
howed an increase in active isoform of caspase-3 in the
earts of WT diabetic mice, but not in the hearts of
T-TG diabetic mice, as shown in Figure 2B. To define
hether apoptosis occurs in cardiomyocytes, double stains
or cardiomyocytes using -sarcomeric actin and active
soform of caspase-3 were examined under confocal laser
canning microscopy (Fig. 2C). Double staining clearly
howed that the activated caspase-3 are localized in
ardiomyocytes (left panel), whereas such staining was
ot observed in the hearts of MT-TG mice (right panel)
glucose (A) and glycated hemoglobin (Hb-A1c) (B) were measured for
s examined by terminal deoxynucleotidyl transferase-mediated dUTP nick
staining images in different groups from diabetic mice 14 days after STZ
TUNEL-positive cells in the cardiac tissues of the diabetic mice from day
For each group, at least 5 mice were used. One-way analysis of variance
t. *p  0.05 versus corresponding control. MT-TG  cardiac-specific,blood
sis wa
NEL
sis of
SD.
on tesr insulin-treated WT diabetic mice (data not shown).
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MT Prevents Diabetic Cell Death and Cardiomyopathy October 17, 2006:1688–97In a previous study, we found that mitochondrial cyto-
hrome c release is one of the critical upstream events leading
o caspase-3 activation and apoptosis in the diabetic heart and
ardiac cells exposed to high levels of glucose (14). In the
resent study, a significant cytochrome c release from mito-
hondria to cytosol in the WT diabetic mice, but not in the
T-TG diabetic mice, was also detected by Western blotting
ssay (Fig. 3). This indicates that MT inhibits mitochondrial
ytochrome c release, resulting in a prevention of caspase-3
ctivation and apoptotic cell death induced by diabetes.
revention of diabetes-induced oxidative/nitrosative
amage in the hearts of MT-TG mice. We recently
emonstrated that MT protection of the heart from diabetes is
igure 2. Caspase-3 activation in the diabetic hearts. Activation of caspase
or the protein expression of its active isoform (B), and double staining for
ice 14 days after STZ treatment. In panel C, “-SA” indicates stainin
taining for active isoform of caspase-3; and “overlay” indicates the overlapp
f each group including more than 3 mice with 2 sections from each mouse
ncluded. One-way ANOVA was used and was followed by the post-hoc
npaired Student t test was used for the rest of the data. *p  0.05 versuainly mediated by suppression of superoxide generation and the associated nitrosative damage (14). To examine whether
he prevention of diabetes-induced cardiac apoptosis is also
elated to the prevention of diabetes-derived nitrosative dam-
ge, we stained the cardiac tissue with antibody against 3-NT,
hich was significantly increased in the WT diabetic mice
Fig. 4A, left panel), but not in the MT-TG diabetic mice
Fig. 4A, right panel). Double staining defines that the
ncreased 3-NT was mainly localized in cardiomyocytes (Fig.
A). In addition, cardiac lipid peroxidation was determined by
BARS assay. Thiobarbituric acid-reactive substance was
ignificantly increased in the WT diabetic heart, but not in the
T-TG diabetic heart (Fig. 4B).
A recent study has demonstrated that mitochondrial oxida-
s measured by enzymatic assay for its activity (A), Western blotting assay
calization (C). Cardiac tissues for both assays were collected from diabetic
cardiomyocytes using -sarcomeric actin; “Csp-3” indicates the specific
these 2 specific stainings. These images in panel C are the representatives
were presented as mean values  SD. In each group, at least 5 mice were
y multiple comparison test for the data from WT mice in A. A 2-tailed
esponding control. Abbreviations as in Figure 1.-3 wa
its lo
g for
ing of
. Data
Tukeive stress, i.e., GSH depletion, is the predominant cause for
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October 17, 2006:1688–97 MT Prevents Diabetic Cell Death and Cardiomyopathyardiac cell death under diabetic condition (17); therefore, in
rder to examine whether MT’s prevention of cardiac cell
eath under diabetic condition is mediated by suppression of
igure 3. Mitochondrial cytochrome c release to cytosol was measured by
estern blotting assay in the cytosolic and mitochondrial fractions from the
earts of control and diabetic mice 14 days after STZ treatment. Gel was a
epresentative of 2 experiments using 3 hearts as 1 sample to isolate the
ytosolic and mitochondrial proteins. A 2-tailed unpaired Student t test was
sed. *p  0.05 versus corresponding control. Abbreviations as in Figure 1.
igure 4. Diabetes-induced cardiac protein nitration and lipid peroxidation
labeled by “-SA”) and protein nitration by 3-NT. These images in pan
ections from each mouse. For panel B, cardiac tissues were collected from
reatment, and lipid peroxidation was measured by thiobarbituric acid-reactive s
-tailed unpaired Student t test was used. *p  0.05 versus corresponding contitochondrial oxidative stress, i.e., GSH depletion, both cy-
osolic and mitochondrial GSH and its oxidized form (GSSG)
ere measured in the present study (Fig. 5). No significant
hange of cytosolic GSH or GSSG was observed either in WT
r MT-TG diabetic mice (Fig. 5A); however, a significant
ecrease in mitochondrial GSH and a significant increase in
itochondrial GSSG were observed in the WT, but not in the
T-TG, diabetic mice (Fig. 5B). Corresponding to the
ncreased conversion of GSH to GSSG, Gpx activity was
ignificantly increased in the cardiac mitochondria of WT
iabetic mice, but not in MT-TG diabetic mice (Fig. 5C). In
ddition, GR activity was also significantly increased in the
T diabetic hearts (Fig. 5C).
reservation of structural normality of the heart in
T-TG diabetic mice. To test our hypothesis that cell
eath, as one of the major early cellular events of the heart
n response to diabetes, is critically involved in the develop-
ent of late-stage cardiomyopathy, cardiac ultrastructure
nd fibrosis were examined in the diabetic mice 6 months
fter STZ treatment. As shown in Figure 6, the hearts of
el A presents the double staining for cardiomyocytes by -sarcomeric actin
are the representatives of each group including more than 3 mice with 2
trol and diabetic mice (at lease 5 mice for each group) 14 days after STZ. Pan
el A
con
ubstance (TBARS) assay. Data were presented as mean values  SD. A
rol. Abbreviations as in Figure 1.
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MT Prevents Diabetic Cell Death and Cardiomyopathy October 17, 2006:1688–97T diabetic mice showed extensive structural abnormali-
ies, including 1) swelled and disrupted mitochondria; 2)
educed and disarranged muscular fibroses with fewer or
rregular Z-lines; 3) chromatin condensation of the nucleus
ith leaked nuclear content (i.e., micronuclear formations);
nd 4) extensively lipid droplets. These changes were rarely
bserved in the hearts of MT-TG diabetic mice (Fig. 6A).
In a previous study, we demonstrated that left ventricular
nd diastolic pressure (LVEDP) was significantly increased
n the WT, but not in the MT-TG, diabetic mice 6 months
fter STZ treatment (19). We assumed that the significant
revention of the increased LVEDP in MT-TG diabetic
ice may result from the MT’s prevention from diabetes-
igure 5. Changes of glutathione (GSH), oxidized glutathione (GSSG), gl
n the diabetic hearts and MT’s effect. The GSH and GSSG conten
lectrochemical method from the cytosolic (A) and mitochondrial (B) frac
he Gpx and GR activities (C) were measured by biochemical assay using c
alues  SD. Animal numbers are 4 to 5 in each group. A 2-tailed unpai
he variables seriously violated the assumptions for normality and homogene
p  0.05 versus WT control. Other abbreviations as in Figure 1.nduced cardiac fibrosis in the MT-TG diabetic mice. To txamine the effect of MT on diabetes-induced fibrosis in the
eart, Sirius-red staining of collagen was performed. A
trong staining of collagen in the hearts of WT diabetic
ice, but not in the hearts of MT-TG diabetic mice, was
bserved (Fig. 6B).
ttenuation of animal mortality in the MT-TG diabetic
ice. Diabetes causes an increase in mortality at late
tage in diabetic patients (1–3), probably because of
ultiple organ dysfunctions including cardiomyopathy.
s shown in Figure 7, WT diabetic mice showed a
ignificant decrease in the survival rate, an effect signifi-
antly prevented in the MT-TG diabetic mice. Although
he mortality may not directly indicate the cardiac effect,
ione peroxidase (Gpx), and glutathione reductase (GR) contents or activity
re measured by high-performance liquid chromatography with a dual
of the control and diabetic tissues from WT and MT-TG diabetic mice.
rcially available kits and visible spectrometer. Data were presented as mean
udent t test was used except for the right panel of B, for which, because
variances, a Welch t test was used. *p 0.05 versus corresponding control;utath
ts we
tions
omme
red St
ity ofhe improved animal survival rate in MT-TG diabetic
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October 17, 2006:1688–97 MT Prevents Diabetic Cell Death and Cardiomyopathyice would relate to MT prevention of diabetic cardio-
yopathy under the conditions of this study, because
ardiac MT overexpression is the only difference between
T and MT-TG mice.
ISCUSSION
he results obtained from the present study demonstrate
hat MT inhibits apoptosis in the diabetic heart of the
ouse model. The inhibition of apoptosis is associated with
uppression of diabetes-caused mitochondrial oxidative
tress, thus a significant suppression of mitochondrial cyto-
hrome c release and caspase-3 activation. Importantly, MT
nhibition of the early-stage apoptosis in the heart of
igure 6. Diabetes-induced ultrastructural changes and fibrotic effect of
xamination (A) for the hearts of diabetic mice 6 months after STZ treatme
n the Materials and Methods section. Fibrosis was evaluated by Sirius-red sta
he semi-quantitative analysis was performed by a computer-image analys
alues  SD. In each group, at least 5 mice were included. A 2-tailed
bbreviations as in Figure 1.iabetic mice results in a prevention of cardiomyopathy at She late stage. In addition, animal survival rate was also
nhanced in the MT-TG diabetic mice as compared to the
T diabetic mice. Therefore, the present study suggests
hat MT prevents the development of diabetic cardiomyop-
thy, at least in part through the attenuation of the
arly-phase cardiac cell death.
The loss of cardiac myocytes is a major cause of the
ompromised cardiac function (8 –10). Apoptosis of car-
iac myocytes and endothelial cells occurs in the hearts
f diabetic patients and STZ-induced diabetic animals
11–17). The present study showed that an average inci-
ence of apoptotic cell death, detected by TUNEL-positive
ells, in the WT diabetic heart from days 7, 14, and 21 after
heart. Ultrastructural evaluation was performed by electron microscopic
set in panel A are the scores for the semi-quantitative analysis as described
of collagen in the hearts of diabetic mice 6 months after STZ treatment (B).
em as described in Materials and Methods. Data were presented as mean
ired Student t test was used. *p  0.05 versus corresponding control.the
nt. In
ining
is syst
unpaTZ treatment is 163 of 106 cells (Fig. 1D). This incidence
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ouse model (14). Kajstura et al. (13), using mice, showed
hat diabetes induced an apoptotic cell death about 4 times
s currently observed. Fiordaliso et al. (12), using rats,
howed a similar incidence of cardiac apoptosis (about 160
f 106 cells at day 10 after STZ treatment) to the current
bservation. The difference for the incidence of cardiac
poptosis in our own studies and those of Kajstura et al. (13)
s unknown, but we used a strain of mice (FVB) which may
e different from mice used by Kajstura et al.
Cell death as a comprehensive consequence of abnormal
ell metabolisms and gene expressions at an early stage in
he heart in response to diabetes may thus be a critical cause
f diabetic cardiomyopathy (4,7,15). This assumption was
upported by a previous study showing that insulin-like
rowth factor 1 (IGF-1) overexpression inhibits cardiac cell
eath in diabetic mice along with a preservation of cardiac
unction (13), and by the present study, which shows that
verexpressing MT in the heart prevents diabetes-induced
arly cell death, leading to a prevention of late cardiomy-
pathy.
In the study with IGF-1 overexpression (13), however,
he cardiomyopathy was examined by cardiac function only
t 7 and 30 days after STZ treatment, and there was also no
nformation about cardiac structural changes. Diabetic car-
iomyopathy is a chronic manifestation at late stage, which
hould be diagnosed by morphological and functional ob-
ervation in a relative long time period (2,3,7). In a recent
tudy we demonstrated the preservation of cardiac function
n MT-TG diabetic mice, whereas WT-diabetic mice
howed a significant cardiac dysfunction at 6 months after
iabetic onset (19). In the present study, under the same
onditions as the previous study (19), we provided further
vidence that cardiac cell death occurred at early stage from
ay 7 to day 21 after STZ treatment. Inhibition of the
arly-phase cell death in the heart of MT-TG diabetic mice
orrelates with a significant prevention of ultrastructural
igure 7. Animal survival rate. Animal survival rate until 4 months was
bserved by 3 separate experiments with at least 10 mice for each group.
ata were presented as mean values  SD. A 2-tailed unpaired Student
test was used. *p  0.05 versus corresponding control (time 0).
bbreviations as in Figure 1.bnormalities and fibrosis in the hearts of diabetic mice 6 conths after STZ treatment. This finding is consistent with
ur recent study using a different transgenic mouse model
hat systemically overexpresses the MT gene to demonstrate
he prevention of MT from diabetes-induced cardiac fibro-
is (23). The preservation of structural normality and
revention of fibrosis in the heart by MT, observed in the
resent study, may be the basis of cardiac functional
ormality of MT-TG diabetic mice 6 months after STZ
reatment, observed in our previous study (19). Further-
ore, the preservation of the cardiac structure and function
n the MT-TG diabetic mice may be responsible for the
igh animal survival rate (Fig. 7).
Oxidative damage caused by ROS and RNS is related
irectly to multiple complications of diabetes (27), including
ardiomyopathy (11–15). A recent study (17) further indi-
ated that mitochondrial oxidative stress such as GSH
epletion is the direct cause for cardiac cell death under the
iabetic condition. We show that MT significantly inhibits
itochondrial GSH depletion, cardiac protein nitration,
nd lipid peroxidation, along with a significant prevention
f cardiac cell death in the hearts of diabetic mice, thus
uggesting the cause–effect relationship of the mitochon-
rial oxidative stress and cardiac cell death. Combined with
ur recent study (19) showing that attenuation of early
xidative damage such as protein nitration (likely belonging
o mitochondrial proteins according to the molecular size)
n the MT-TG diabetic heart resulted in a significant
revention of diabetes-caused cardiac dysfunction observed
months after STZ treatment, it strongly suggests that
xidative stress is a critical cause of early-phase cardiac cell
eath.
Metallothionein cooperation with GSH to maintain cel-
ular redox status has been implicated (28,29). We have
hown that there is no significant change in the total GSH,
px, and GR levels in the hearts of MT-TG mice com-
ared to WT mice under physiological conditions (22).
owever, GSSG contents in both cytosolic and mitochon-
rial portions were significantly lower in MT-TG hearts
han those in WT hearts even under physiological condi-
ions (i.e., in control groups; Figs. 5A and 5B), suggesting
he prevention of oxidization of GSH under physiological
onditions. We recently confirmed the existence of MT
isulfide bonds in the MT-TG hearts under physiological
onditions and further increased formation of MT disulfide
onds under oxidative stress conditions (30), suggesting the
nteraction of MT with ROSs or RNSs. In our previous
tudy (28), it was shown that in the presence of a high
oncentration of MT, the primary antioxidant defense
gainst ROS and/or RNS would shift from GSH to MT;
herefore, there was no increase in mitochondrial GSSG in
he hearts of MT-TG diabetic mice even though there was
significant increase in GSSG in the cardiac mitochondria
f WT diabetic mice. In the hearts of WT diabetic mice,
he increased GSSG that was associated with increased Gpx
ctivity (Fig. 5) may cause the adaptive increase in mito-
hondrial GR activity in the hearts of WT diabetic mice
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emains unclear on the basis of the present study. We have
emonstrated the overproduction of superoxide in the
earts of WT diabetic mice 2 weeks after STZ treatment
19). The overproduced superoxide may be converted to
ydrogen peroxide, which may in turn stimulate the cells to
ncrease Gpx activity in order to compensate.
In summary, the present study, in combination with our
ecent studies (14,19,23), demonstrates that diabetes causes
ardiac mitochondria cytochrome c release-dependent apo-
tosis at early stage. Metallothionein significantly inhibits
iabetes-caused early cardiac apoptosis through suppression
f mitochondrial oxidative stress (i.e., GSH depletion)
eading to a significant prevention of the development of
iabetic cardiomyopathy. Although the precise mechanisms
nderlying how MT protects from diabetes-caused mito-
hondrial GSH depletion remain to be explored, the
linical implication of MT’s cardiac prevention from
iabetes is critically important, since zinc supplementa-
ion given to diabetic mice significantly prevented the
evelopment of diabetic cardiomyopathy through cardiac
T induction (31).
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